Improved Multiple Sclerosis Lesion Detection using an Intelligent Automation Software

Christian Federau[1,2,*], Nicolin Hainc[2,3], Myriam Edjlali[4,5], Guangming Zhu[6], Milica

Mastilovic[4,7], Nathalie Nierobisch[2,3], Jan-Philipp Uhlemann[2,3], Silvio Paganucci[1],

Cristina Granziera[8], Olivier Heinzlef[9,10], Lucas B. Kipp[11], Max Wintermark[5,12]

[1] AI Medical AG, Zollikon, Switzerland

[2] University of Zürich, Zürich, Switzerland

[3] Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich,

University of Zurich, Zurich, Switzerland

[4] Department of Radiology, APHP, Hôpitaux Raymond-Poincaré & Ambroise Paré, DMU Smart

Imaging, GH Université Paris-Saclay, U 1179 UVSQ/Paris-Saclay, Paris, France

[5] Laboratoire d'imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS,

Inserm, Service Hopsitalier Frédéric Joliot, Orsay, France.

[6] Stanford University, Stanford, USA

[7] Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

[8] University Hospital Basel and University of Basel, Basel, Switzerland

[9] Department of Neurology, Poissy-Saint-Germain-en-Laye Hospital, Poissy, France

[10] CRC SEP IDF Ouest, Poissy-Garches, France

[11] Department of Neurology & Neurological Sciences, Stanford University School of Medicine,

Stanford, CA, USA

[12] MD Anderson Cancer Center, Houston, USA

*Corresponding Author: Christian Federau, AI Medical AG, Goldhaldenstr 22a, 8702 Zollikon,

Switzerland. <surname> at ai-medical.ch

Abstract

Introduction

The assessment of multiple sclerosis (MS) lesions on follow-up magnetic resonance imaging (MRI)

is tedious, time-consuming, and error-prone. Automation of low-level tasks could enhance the

radiologist in this work. We evaluate the intelligent automation software Jazz in a blinded three

centers study, for the assessment of new, slowly expanding, and contrast-enhancing MS lesions

Methods

In three separate centers, 117 MS follow-up MRIs were blindly analyzed on FLuid Attenuated

Inversion Recovery (FLAIR), pre- and post-Gadolinium T1-weighted images using Jazz by 2

neuroradiologists in each center. The reading time was recorded. The ground truth was defined

in a second reading by side-by-side comparison of both reports from Jazz and the standard clinical

report. The number of described new, slowly expanding, and contrast-enhancing lesions

described with Jazz was compared to the lesions described in the standard clinical report.

Results

A total of 96 new lesions from 41 patients and 162 slowly expanding lesions (SELs) from 61

patients were described in the ground truth reading. A significantly larger number of new lesions

were described using Jazz compared to the standard clinical report (63 versus 24). No SELs were

reported in the standard clinical report, while 95 SELs were reported on average using Jazz. A

total of 4 new contrast-enhancing lesions were found in all reports. The reading with Jazz was

very time efficient, taking on average 2min33sec $\pm$ 1min0sec per case. Overall inter-reader

agreement for new lesions between the readers using Jazz was moderate for new lesions (Cohen

kappa=0.5) and slight for SELs (0.08).

Discussion

The quality and the productivity of neuroradiological reading of MS follow-up MRI scans can be

significantly improved using a dedicated software such as Jazz.

Introduction

Multiple sclerosis (MS) is an autoimmune, potentially disabling demyelinating disease of the central nervous system (CNS), with clinical onset typically in the young adult. [1] Traditionally, MS progression have been categorized in three main type, Primary-Progressive MS (PPMS) affecting between 10 and 15 % of MS patients, Relapsing-Remitting MS (RRMS) and Secondary-Progressive MS (SPMS), [1] although it has been recently suggested that the clinical course of MS is better described as a continuum, with contributions from concurrent pathophysiological processes that vary across individuals and over time. [2] Prior to the availability of the disease-modifying therapies, roughly 50% of patients diagnosed with RRMS would transition to SPMS within 10 years, and 90% would transition within 25 years, with a median time of about 19 years. [3] The diagnosis of SPMS is most often established retrospectively, [4] on average 3 years after the actual progression started. [5]

This is caused by the difficulties by the clinicians and the patients to interpret the initial symptoms indicating early progression, which they can be subtle and fluctuating, [4] and by the difficulties to detect disease progression on imaging. The importance of detecting remaining inflammatory disease earlier and more systematically has further increased with the demonstration that early intervention with high-efficacy disease modifying therapies can delay the onset of SPMS, [6] and with the recent availability of approved new therapies for progressive MS, such as the anti-CD20 monoclonal antibody Ocrelizumab [7] or the selective sphingosine-1-phosphate receptor modulator Siponimod. [8]

MS disease monitoring with imaging is particularly challenging. It involves at least yearly follow-up magnetic resonance imaging (MRI) scans of their central nervous system, and consists of the tedious, time-consuming, and error-prone manual comparison and counting of the multiple demyelinating lesions. Given time constraints and the fact lesion burden can reach hundreds in severe cases, neuroradiologists can be forced to grossly compare the lesion load, and relevant disease evolution might remain unnoticed for some time. Longitudinal subtraction maps have been used to increase sensitivity for detecting new or enlarged lesions multiple sclerosis lesions[9−]

[12] and reduce reading time[13], but small lesions might be difficult to detect using this technique.

[14]

Fully automated neuroradiological reporting of MS lesion load evolution would be of great

interest, but current methods, including deep learning methods, have currently limited

practicality given they are far from error free. In the last decade, deep learning methods, in

particular two-dimensional and three-dimensional convolutional neural networks, have been

applied to develop automatic lesion detection and segmentation. [15] Reported lesion-wise true

positive rate ranges between 0.15 and 0.57, and the lesion-wise false positive rate ranges

between 0.08 and 0.68. [16–25] Those numbers are relatively low, given that every single new or

evolving lesion on a follow-up control can be considered a marker of disease progression

requiring a re-evaluation of the patient's current therapy, and therefore, the expert radiologist

assessment is still required for every patient. [26]

In this context, a tool based on intelligent automation, which could simplify the work of the

radiologist by automating many repetitive tasks, would be of interest. Intelligent automation

aims to streamline processes to improve efficiency and reduce errors. [27] It applies the concept of

breaking larger complex tasks into several simpler, very-well-understood low-level steps, and

automatizes the low-level steps with intelligent software, using artificial intelligence and

advanced software engineering. By freeing the radiologist to concentrate on the lesion

assessment, it could reduce the number of missed lesions. Intelligent automation promises to

improve productivity, reduce costs, as well as more precise processes and a better user

experience. Jazz [28] is an intelligent automation software dedicated for neuroradiology, that

automates multiple low-level tasks such as contrast recognition, previous exams organization,

and images coregistration. It includes a semi-automatic lesion annotation tool, permitting the

user to easily save all relevant information in a lesion list, and has a graphical user interface

intended to maximize productivity and to minimize operator fatigue and discomfort. **(Figure 1)**

In this retrospective study, we evaluate Jazz for the assessment of new, expanding, and contrast-
enhancing MS lesions, blindly in three centers, and compared the reported lesions with the
lesions described in the standard clinical report.

Methods

The following analysis was performed in three separate centers in a fully blinded and
independent manner.

Dataset

A set of 120 (40 from each of the 3 centers) current and prior magnetic resonance examinations
of patients diagnosed with MS were obtained. 3D FLAIR, pre- and post-Gadolinium T1-weighted
3D sequences, as well as the corresponding clinical report, were analyzed. (**Table 1**) All data were
anonymized.

Case Reading using Jazz

The cases were loaded in Jazz. In a pre-processing step, Jazz automatically coregistered the
images to one another using an affine transformation and labelled their contrast. The reader
used then Jazz user interface to switch between the coregistered exams and contrasts using
single-click operations or using the corresponding keyboard short-cut to evaluate the lesions. If
necessary, the reader used the lesion locking tool to evaluate the lesion in different planes. When
the user detected a new, SEL, or contrast-enhancing lesion, the reader used Jazz lesion
annotation tool, which permits marking of observed lesions with a single click, wherein the
software automatically recognized the anatomical lesion location, and used if necessary the
interactive lesion list with picker menus to correct the lesion description if necessary. (**Figure 1**)

In each center, two neuroradiologists evaluated independently all 40 cases using the Jazz
software (center 1 __Blinded for Review__, 12 years of experience, and __ Blinded for Review__,
8 years of experience, center 2, __Blinded for Review__, 15 years of experience, and __ Blinded

for Review__, 2 years of experience, center 3 __Blinded for Review__, 5 years of experience, and

__ Blinded for Review__, 3 years of experience). The new lesions and the slowly expanding lesions

(SELs) were assessed on the 3D FLAIR. New lesions were defined as non-preexisting white matter

lesions on the previous exam, visible on the current exam, while SELs were defined as preexisting

white matter lesions that demonstrate lesions expansion between previous and current exam.

The contrast-enhancing lesions were assessed by comparing the pre- and post-GAD T1-weighted

3D sequences. Reading time was recorded.

<u>Ground Truth</u>

A ground truth was defined by reevaluating, using side-by-side comparison, all lesions described

in the standard clinical reports and the reports generated by Jazz. The ground truth reading was

done by either the most experienced reader of both readers (in two centers), or by a third

experienced reader (third center, __Blinded for Review__, 8 years of experience). Reported new

lesions, SELs, and contrast-enhancing lesions in each report were then counted, and classified as

true positive, false negative, or false positive.

<u>Statistical Analysis</u>

Statistical significance was assessed using the Mann-Whitney U test between the average reading

time with Jazz and generating the standard report. Significance level was set to $\alpha < 0.05$. Inter-

reader agreement between the readers using Jazz was assessed using Cohen's Kappa.

Results

<u>Patient Population</u>

39 cases were included from center 1 (mean age 55.5 ± 10.6 y, median age 57 y, age range 25-72

y, female / male = 30 / 9; one case was excluded because the lesions were very confluent,

rendering the comparison of separate lesions difficult). 40 cases were included from center 2

(mean age 48.3 ± 12.8 y, median age 45 y, age range 26-73 y, female / male = 31 / 9). 38 cases

were included from center 3 (mean age 35.4 ± 9.8 y, median age 34 y, age range 20-64 y, female

/ male = 20 / 18; one case was excluded because the follow-up MRI was done for hydrocephalus

evaluation without dedicated description of the MS lesions, and one case was excluded because

the 3D FLAIR was missing in one of the exams).

<u>Reading time</u>

Reading time using Jazz took on average 2 min 33 sec $\pm$ 1 min 0 sec per case for all readers (**Figure**

2). In center 1, reading using Jazz took 2 min 29 sec $\pm$ 2 min 15 sec per case for reader 1, and 1

min 45 sec $\pm$ 51 sec for reader 2. In center 2, reading using Jazz took 4 min 30 sec $\pm$ 2 min 42 sec

per case for reader 1, and 2 min 33 sec $\pm$ 1 min 12 sec for reader 2. In center 3, reading using Jazz

took 2 min 12 sec $\pm$ 1 min 7 sec per case for reader 1, and 1 min 51 sec $\pm$ 1 min 4 sec for reader

2.

<u>New Lesions on 3D FLAIR</u>

In all three centers, the ground truth reading reported an average of 0.83 ± 0.08 new lesions per

case (a total of 96 lesions from 41 patients, out of a total of 117 patients). The standard clinical

reports reported 24 true positive new lesions from 13 patients, 72 false negative, and 5 false

positive new lesions. The Jazz report reported on average (average of 2 readers) 63 true positive

lesions from 30.5 patients, 33 false negative, and 18 false positive new lesions ($p < 0.05$; **Table 1**

and Figure 3).

<u>Slowly Expanding Lesions on 3D FLAIR</u>

In all three centers, the ground truth reading reported an average of 1.39 ± 0.72 SELs per case (a

total of 162 lesions from 61 patients, out of a total of 117 patients). The standard clinical reports

reported no growing lesions at any center. The Jazz reports reported on average (average of 2

readers) 95 true positive growing lesions from 45 patients, 67 false negative, and 38.5 false

positive SELs ($p < 0.05$; **Table 2 and Figure 4**).

<u>Contrast-enhancing Lesions</u>

In center 1, all patients were administered intravenous contrast, and no contrast-enhancing

lesions were described in any report. In center 2, 11 patients were not administered intravenous

contrast; in the remaining 29 patients, 4 new contrast-enhancing lesions were described,

consistently in all reports, and 1 false positive contrast-enhancing lesion was described on the

standard clinical report only. In center 3, all patients except one were administered intravenous

contrast; one contrast-enhancing lesion was described, consistently in all reports.

Inter-reader Agreement

Overall inter-reader agreement for new lesions between the readers using Jazz was moderate,

with kappa = 0.5 (center 1: 0.45, center 2: 0.51, center 3: 0.54) and for SELs it was slight, with

kappa = 0.08 (center 1: -0.3, center 2: 0.3, center 3: 0.22).

Statement

This study was approved by the Ethic committee of the Université Paris, of the Canton of Zürich

(2022-00041) and of Stanford University (IRB-26147). All methods were carried out in accordance

with relevant guidelines and regulations. Informed consent from the subjects was waived by the

above-mentioned ethic committee. The datasets used and analyzed during the current study

available from the corresponding author on reasonable request.

Discussion

This study shows that a significantly larger number of new and SELs are reported when using the

intelligent automation software Jazz compared to the standard clinical reporting method in a

time efficient manner, by allowing the neuroradiologist to concentrate on the detection and

evaluation of lesions. By permitting to toggle between coregistered current and previous exams,

it uses a particularly potent neurophysiological mechanism to attract the attention of the reader

to modifications in the images, in other words in the case of MS, to new and evolving lesions.

Indeed, attention is a selective process and is physiologically necessary, because there are severe

limits on our capacity to process visual information. [29] A theory suggests that attention is imposed

by the fixed amount of overall energy available to the brain, and that because of the high-energy

cost of neuronal activity, only a small fraction of the machinery can be engaged concurrently. [29]

As a consequence, stimuli have to compete for limited resources, [30] a notion that is supported by

electrophysiological, neuroimaging and behavioral studies. [31,32] Of the several visual stimuli that

are known to capture attention, the sudden appearance of a new object and the sudden changes

of an object are known to be particularly potent and to influence priority in visual search. [33–35]

This mechanism is exploited in the dynamic switching tool of Jazz, compared to a standard side-

by-side comparison method.

The identification of progression in MS is typically retrospective and based on clinical symptoms.

[36] Most clinical trials rely on an increase in Expanded Disability Status Scale score confirmed over

3 or 6 months to define disease progression, and might overestimate the accumulation of

permanent disability by up to 30%. [37] Given the profound burden of progressive MS and the

recent development of effective treatments for these patients, there is a need to establish

reliable and reproducible methods for identifying progression early in the disease course.

Neuroradiological MRI reports of MS are often sparse and not standardized, despite the

advantages of standardization of clinical data for MS monitoring being well recognized. [38]

Structured reports of MRI in patients with MS have been shown to provide more adequate

information for clinical decision making than nonstructured reports. [39] Improvement in the

digitization of real-world patient data could foster new insights into the epidemiology and

pathophysiology of the disease, and are ultimately necessary to achieve truthful personalized

patient care. [40]

This study also shows that at least one SEL was described in more than half of all patients, while

none were reported in the standard clinical reports. The inter-reader agreement was low though,

showing that this assessment remains particularly difficult and prone to subjectivity. The use of

objective criteria defining SELs might help to improve this aspect. SELs can be easily overlooked,

and are particularly difficult to detect in a standard DICOM viewer. There is substantial interest

in SELs as a potential marker of chronic but active MS lesions [41–43] which may have diagnostic,

prognostic and treatment implications. SELs were found to be more prevalent in patients with

primary progressive MS (PPMS) compared with patients with relapsing-remitting MS (RRMS). [42]

The proportion of SELs and their microstructural tissue abnormalities were associated with a

higher risk of MS progression and secondary progressive MS (SPMS) conversion. [44] In SPMS, SELs

were found to represent almost one-third of T2 lesions, associated with neurodegenerative MRI

markers and related to clinical worsening. [45] Therefore the number and volume of SELs are a

promising biomarker to predict a more active, progressive disease course and could become a

new target for therapeutic intervention. This is particularly interesting, because recent advances

in our understanding of the mechanisms that drive SELs have fueled optimism for improved

treatment of this condition. [46] A robust tool to gather SELs on magnetic resonance images, such

as the one described in this work, might help to detect patients with progressive disease earlier

and more systematically.

This study suffers from several limitations. Only three centers were included, and our results may

not generalize to other centers. The reading using the Jazz software was not under identical

conditions to the reading employed to generate the standard report, which was done during the

standard clinical routine and might have included more distracting events. The reading of the

standard clinical reports included at least a first reading and a second reading through a

supervisor, and discussion with, and comments from the referring clinicians might have occurred.

The reading with the Jazz software only included a single reading from a single reader. The ground

truth was not based on a consensus reading performed by the most experienced reader in each

center, which might have biased the agreement. Current and previous exams could have been

acquired on different scanners, which might be a cofounder in the SEL evaluation. Further, a

previous definition of SELs was based on the inclusion of a least three time points over more than

two years, [42] with local expansion assessed by the Jacobian determinant of the deformation

between reference and follow-up scans, and a heuristic scored was used to favor individual SEL

candidates undergoing concentric and constant change, [42] while here, a more pragmatic

approach was considered, using the subjective expansion assessment based on only two MR time

points. Finally, no standardized method was used to define the SELs, as the evaluation was left

to the subjective appraisal of each reader.

In conclusion, this study shows that significantly more new lesions and SELs can be described in

a time-efficient manner using the intelligent automation software Jazz compared to the standard

method.

Tables

	Ground Truth	Jazz Reader 1	Jazz Reader 2	Jazz Reader Average	Standard Clinical Report
Center 1	12	5	12	8.5	3
Center 2	11	9	10	9.5	4
Center 3	18	13	12	12.5	6
Total	**41**	**27**	**34**	**30.5**	**13**

291   **Table 1.** Number of patients with true positive new lesions.

	Ground Truth	Jazz Reader 1	Jazz Reader 2	Jazz Reader Average	Standard Clinical Report
Center 1	13	12	5	8.5	0
Center 2	29	27	19	23	0
Center 3	19	18	9	13.5	0
Total	**61**	**57**	**33**	**45**	**0**

297   **Table 2**. Number of patients with true positive SELs.

298
299
300
301

Figures

1. The intelligent automation software automizes low-level tasks for the radiologists, including

(**A**) automatic contrast recognition, exams ordering, and (**B**) image coregistration for fast "single-

click" lesion comparison and evaluation "without eye movements", maximizing efficiency and

minimizing errors. (**C**) Lesion locking, which permits the evaluation of the lesion in various plane

with a "single-click". (**D**) Automatic anatomic localization and lesion tracking permits ultra-fast

lesion navigation. The pre-populated drop-down pickers allow for fast corrections of lesion

characteristics. From the lesion list, the software counts the lesions, summarizes the findings,

and generates a report automatically, which permits an additional gain in time. Automated lesion

counting and generation of a standardized, editable report, including overview figures of the

lesions, saves additional time for the radiologist, and eliminates possible human errors in this

step.

2. Histogram of the reading time by each reader in the three centers using Jazz.

3. Examples of missed lesions on the standard report, detected by both readers with the Jazz

software.

| Current exam | Previous exam | Current exam | Previous exam |

324 4. Examples of SELs not described on the standard clinical report, but described by both readers

325 with the Jazz software. Note that all those images were acquired from the same patient. While

326 the presence of a single SEL might be often difficult to interpret, as it might occur from partial

327 volume effects or from MRI artifacts, the presence of multiples SELs is highly suggestive of disease

328 progression.

Data Statement

The data that support the findings of this study are available from the corresponding author, C.F., on reasonable request.

References

1.   Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The
Lancet. 2018;391:1622–1636.

2.   Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new
mechanism-driven framework. The Lancet Neurology. 2023;22:78–88.

3.   Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive
multiple sclerosis: current knowledge and future challenges. The Lancet Neurology.
2006;5:343–354.

4.   Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med.
2018;8:a028928.

5.   Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to
secondary progressive multiple sclerosis. Mult Scler. 2014;20:1654–1657.

6.   Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy
With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019;321:175.

7.   Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022;82:323–334.

8.   Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive
multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet.
2018;391:1263–1273.

9.   Moraal B, Wattjes MP, Geurts JJG, et al. Improved Detection of Active Multiple Sclerosis
Lesions: 3D Subtraction Imaging. Radiology. 2010;255:154–163.

10. Eichinger P, Wiestler H, Zhang H, et al. A novel imaging technique for better detecting new
lesions in multiple sclerosis. J Neurol. 2017;264:1909–1918.

11. Eichinger P, Schön S, Pongratz V, et al. Accuracy of Unenhanced MRI in the Detection of
New Brain Lesions in Multiple Sclerosis. Radiology. 2019;291:429–435.

12. Tan IL, Van Schijndel RA, Pouwels PJW, Adèr HJ, Barkhof F. Serial Isotropic Three-
Dimensional Fast FLAIR Imaging: Using Image Registration and Subtraction to Reveal
Active Multiple Sclerosis Lesions. American Journal of Roentgenology. 2002;179:777–782.

13. Schmidt MA, Linker RA, Lang S, et al. FLAIRfusion Processing with Contrast Inversion:
Improving Detection and Reading Time of New Cerebral MS Lesions. Clin Neuroradiol.
2018;28:367–376.

14. Ganiler O, Oliver A, Diez Y, et al. A subtraction pipeline for automatic detection of new
appearing multiple sclerosis lesions in longitudinal studies. Neuroradiology. 2014;56:363–
374.

15. Afzal HMR, Luo S, Ramadan S, Lechner-Scott J. The emerging role of artificial intelligence in
multiple sclerosis imaging. Mult Scler. 2022;28:849–858.

16. Aslani S, Dayan M, Storelli L, et al. Multi-branch convolutional neural network for multiple
sclerosis lesion segmentation. NeuroImage. 2019;196:1–15.

17. Hashemi SR, Salehi SSM, Erdogmus D, Prabhu SP, Warfield SK, Gholipour A. Asymmetric
Loss Functions and Deep Densely Connected Networks for Highly Imbalanced Medical
Image Segmentation: Application to Multiple Sclerosis Lesion Detection. IEEE Access.
2019;7:1721–1735.

18. Andermatt S, Pezold S, Cattin PC. Automated Segmentation of Multiple Sclerosis Lesions
Using Multi-dimensional Gated Recurrent Units. In: Crimi A, Bakas S, Kuijf H, Menze B,
Reyes M, editors. Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain
Injuries. Cham: Springer International Publishing; 2018. p. 31–42.

19. Valverde S, Cabezas M, Roura E, et al. Improving automated multiple sclerosis lesion
segmentation with a cascaded 3D convolutional neural network approach. NeuroImage.
2017;155:159–168.

20. Maier O, Handels H. MS lesion segmentation in MRI with random forests. Proc
Longitudinal Multiple Sclerosis Lesion Segmentation Challenge, 2015. :1–2.

21. Birenbaum A, Greenspan H. Longitudinal Multiple Sclerosis Lesion Segmentation Using
Multi-view Convolutional Neural Networks. In: Carneiro G, Mateus D, Peter L, et al.,
editors. Deep Learning and Data Labeling for Medical Applications. Cham: Springer
International Publishing; 2016. p. 58–67.

22. Deshpande H, Maurel P, Barillot C. Adaptive dictionary learning for competitive
classification of multiple sclerosis lesions. 2015 IEEE 12th International Symposium on
Biomedical Imaging (ISBI) [online]. Brooklyn, NY, USA: IEEE; 2015. p. 136–139. Accessed at:
http://ieeexplore.ieee.org/document/7163834/. Accessed October 22, 2021.

23. Jain S, Sima DM, Ribbens A, et al. Automatic segmentation and volumetry of multiple
sclerosis brain lesions from MR images. NeuroImage: Clinical. 2015;8:367–375.

24. Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian Model
Selection for Pathological Neuroimaging Data Applied to White Matter Lesion
Segmentation. IEEE Trans Med Imaging. 2015;34:2079–2102.

25. Tomas-Fernandez X, Warfield SK. A Model of Population and Subject (MOPS) Intensities
With Application to Multiple Sclerosis Lesion Segmentation. IEEE Trans Med Imaging.
2015;34:1349–1361.

26. Hainc N, Federau C, Stieltjes B, Blatow M, Bink A, Stippich C. The Bright, Artificial
Intelligence-Augmented Future of Neuroimaging Reading. Front Neurol. 2017;8:489.

27. Wikipedia - Intelligent automation [online]. Accessed at:
https://en.wikipedia.org/wiki/Intelligent_automation. Accessed January 1, 2023.

28. Jazz [online]. AI Medical AG; Accessed at: www.ai-medical.ch.

29. Carrasco M. Visual attention: The past 25 years. Vision Research. 2011;51:1484–1525.

30. Kinchla RA. Attention. Annu Rev Psychol. Annual Reviews; 1992;43:711–742.

31. Beck DM, Kastner S. Top-down and bottom-up mechanisms in biasing competition in the
human brain. Vision Research. 2009;49:1154–1165.

32. Reynolds JH, Chelazzi L. Attentional Modulation of Visual Processing. Annu Rev Neurosci.
2004;27:611–647.

33. Enns JT, Austen EL, Lollo VD, Rauschenberger R, Yantis S. New Objects Dominate
Luminance Transients in Setting Attentional Priority. :16.

34. Yantis S, Hillstrom AP. Stimulus-driven attentional capture: Evidence from equiluminant
visual objects. Journal of Experimental Psychology: Human Perception and Performance.
1994;20:95–107.

35. Yantis S, Jonides J. Abrupt visual onsets and selective attention: Evidence from visual
search. Journal of Experimental Psychology: Human Perception and Performance.
1984;10:601–621.

36. Filippi M, Preziosa P, Langdon D, et al. Identifying Progression in Multiple Sclerosis: New
Perspectives. Ann Neurol. 2020;88:438–452.

37. Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple
sclerosis. Brain. 2015;138:3287–3298.

38. D'Souza M, Papadopoulou A, Girardey C, Kappos L. Standardization and digitization of
clinical data in multiple sclerosis. Nat Rev Neurol. 2021;17:119–125.

39. Alessandrino F, Pichiecchio A, Mallucci G, et al. Do MRI Structured Reports for Multiple
Sclerosis Contain Adequate Information for Clinical Decision Making? American Journal of
Roentgenology. 2018;210:24–29.

40. Voigt I, Inojosa H, Dillenseger A, Haase R, Akgün K, Ziemssen T. Digital Twins for Multiple
Sclerosis. Front Immunol. 2021;12:669811.

41. Calvi A, Haider L, Prados F, Tur C, Chard D, Barkhof F. In vivo imaging of chronic active
lesions in multiple sclerosis. Mult Scler. Epub 2020 Sep 23.:135245852095858.

42. Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic
resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler.
2019;25:1915–1925.

43. Elliott C, Belachew S, Wolinsky JS, et al. Chronic white matter lesion activity predicts
clinical progression in primary progressive multiple sclerosis. Brain. 2019;142:2787–2799.

44. Preziosa P, Pagani E, Meani A, et al. Slowly Expanding Lesions Predict 9-Year Multiple
Sclerosis Disease Progression. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1139.

45. Calvi A, Carrasco FP, Tur C, et al. Association of Slowly Expanding Lesions on MRI With
Disability in People With Secondary Progressive Multiple Sclerosis. Neurology.
2022;98:e1783–e1793.

46. Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in
progressive multiple sclerosis. Nat Rev Neurol. 2022;18:40–55.